Hypertrophic cardiomyopathy: From molecular and genetic mechanisms to clinical management

European Heart Journal, Supplement

Volumn 3, Issue L, 2001, Pages

  Watkins, Hugh ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AMP kinase; Cardiomyopathy; Contractile proteins; Energetics; Genes

Indexed keywords

TROPONIN T;

ARTICLE; CARDIOMYOPATHY; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; FAMILY HISTORY; GENE MUTATION; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR GENETICS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SARCOMERE;

EID: 0035149929     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90064-1     Document Type: Article

References (43)

1. A molecular basis for familial Hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation
2. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere
3. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy
4. Mutations in the cardiac myosin binding protein-C on chromosome 11 cause familial Hypertrophic cardiomyopathy
5. Mutations in either the essential or regulatory light chains are associated with a rare myopathy in human heart and skeletal muscle
6. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
7. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy
8. Structural analysis of the titin gene in Hypertrophic cardiomyopathy: Identification of a novel disease gene
9. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy
10. A mutant tropomyosin that causes hypertrophic cardiomyopathy is incorporated in vivo and associated with an increased calcium sensitivity
11. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action
12. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults
13. Familial hypertrophic cardiomyopathy: From mutations to functional defects
14. Human cardiac myosin binding protein C mutations cause late-onset familial cardiac hypertrophy
15. Experience from clinical genetics in hypertrophic cardiomyopathy: Proposal for new diagnostic criteria in adult members of affected families
16. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. A prospective study
17. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy
18. Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
19. Counselling issues in familial hypertrophic cardiomyopathy
20. Characteristics and prognostic implications of myosin missense mutations in familial Hypertrophic cardiomyopathy
21. Differences in clinical expression of Hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A Leu908Val mutation and a Arg403Gln mutation
22. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3
23. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy
24. Sudden death due to troponin T mutations
25. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis
26. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
27. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms
28. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy
29. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, deltasarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex
30. Mutations in the β-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin binding protein-C
31. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: Insights into disease pathogenesis and troponin function
32. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy
33. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alphatropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay
34. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy
35. Mutations in the δ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis
36. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy
37. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA (glycine) gene
38. Recent advances in the molecular pathogenesis of Friedreich ataxia
39. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children
40. The AMP-activated protein kinase: Fuel gauge of the mammalian cell?
41. Dealing with energy demand: The AMP-activated protein kinase
42. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy